Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Retained Earnings (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Retained Earnings for 13 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.69% to $16.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.4 million, a 100.69% increase, with the full-year FY2025 number at $16.4 million, up 100.69% from a year prior.
  • Retained Earnings was $16.4 million for Q4 2025 at Iovance Biotherapeutics, up from $16.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $20.9 million in Q2 2025 to a low of -$2.5 billion in Q1 2025.
  • A 3-year average of -$1.3 billion and a median of -$1.8 billion in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: dropped 26.83% in 2024, then skyrocketed 100.69% in 2025.
  • Iovance Biotherapeutics' Retained Earnings stood at -$2.0 billion in 2023, then dropped by 18.49% to -$2.4 billion in 2024, then soared by 100.69% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Retained Earnings are $16.4 million (Q4 2025), $16.1 million (Q3 2025), and $20.9 million (Q2 2025).